- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Overview of Available Third-Line Options in mCRC
Panelists discuss how available third-line therapies, such as FTD/TPI, regorafenib, and others, are chosen based on survival data, safety, and patient quality of life.
Panelists discuss the therapeutic landscape for metastatic colorectal cancer once patients progress to third-line treatment. They outline the available agents, including trifluridine/tipiracil (FTD/TPI), regorafenib, and newer targeted therapies, emphasizing how trial data inform their integration into practice.
The RECOURSE trial plays a central role in establishing FTD/TPI as a viable option, with its demonstrated improvements in overall survival and a manageable safety profile. Clinicians highlight how such data provide confidence in recommending therapy beyond standard second-line regimens.
Ultimately, they stress that treatment choice must balance efficacy with tolerability to ensure quality of life for patients already heavily pretreated.
Physician Peer Influence Drives Uptake of Opportunistic Salpingectomy for Ovarian Cancer Prevention
October 9th 2025Surgeons are more likely to perform opportunistic salpingectomy when their peers have done so, underscoring the impact of physician networks in ovarian cancer prevention.
Read More
